Search This Blog

Wednesday, January 8, 2020

NMC Health, Finablr stocks hit after major investors sell shares

Shares in NMC Health and Finablr plunged after two major shareholders launched a discounted share sale in the London-listed groups, weeks after NMC was hit by a short-selling attack by U.S. firm Muddy Waters.

The healthcare firm’s vice-chairman Khaleefa Al Muhairi and its second-largest shareholder Saeed Al Qebaisi have together sold NMC shares worth 375 million pounds.
The deal was priced at 1,200 pence per share, a bookrunner said on Wednesday, adding that the sale was oversubscribed. The price is at a discount of about 20% to NMC’s last close of 1,494.5 pence in London.
Qebaisi and Muhairi have also sold shares worth about $72 million in payments firm Finablr, which is co-chaired by Bavaguthu Raghuram Shetty, also the founder and co-chairman of NMC.
Shares in Finablr, whose ransomware-hit Travelex unit is also chaired by Muhairi, were sold at 135 pence per share, a discount of nearly 13%, sending shares to a record low.
NMC shares were down 15.8% at 1,258.5 pence.
The investors sold the shares to repay some of their debt and the debt of some corporate entities owned by them, the bookrunner said, adding that the move will also remove the pledge on NMC shares under a borrowing agreement with two banks.
The sale was not related to NMC’s operating performance or long-term prospects, the firm said in a statement, adding the shareholders “remain supportive”.
Finablr was not immediately available for comment.
Following the transactions, Muhairi will retain a 12.5% stake in NMC while Qebaisi will keep a 4.7% holding, the bookrunner said, adding that they jointly hold roughly an additional 7% in NMC through Infinite Investment.
Reuters reported https://in.reuters.com/article/us-nmc-health-m-a-exclusive/exclusive-two-groups-one-backed-by-chinas-fosun-bid-for-nmc-health-stake-sources-idINKCN1VB20R last year that two groups were bidding for a 40% stake in NMC, which was jointly owned by UAE-based businessman Qebaisi, Muhairi, and Infinite Investment.
Reuters could not immediately reach the investors for comment.
NMC, the United Arab Emirates’ largest private healthcare provider, has launched an independent review of its finances after short-seller Muddy Waters questioned the value of its assets and cash balance while announcing a short position.
Earlier this week NMC said the review will initially assess its cash balances as of Dec. 15.
Short selling involves borrowing an asset and selling it with the aim of buying it back at a cheaper price for profit.
Muddy Waters, founded by American Carson Block, is known in financial markets for declaring short equity positions on the basis of in-house research.
At Wednesday’s session low, NMC, which has denied the allegations, had lost nearly 3 billion pounds in market value since the report was launched.

More healthcare new coverage ahead of JPM20

Agilent (NYSE:A) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo.
Avantor (NYSE:AVTR) initiated with Overweight rating and $22 (17% upside) price target at Wells Fargo. Shares down 1% premarket.
Axonics Modulation Technologies (NASDAQ:AXNX) initiated with Buy rating and $38 (41% upside) price target at SunTrust.
Bio-Rad Laboratories (NYSE:BIO) initiated with Overweight rating and $430 (13% upside) price target at Wells Fargo.
BioLife Solutions (NASDAQ:BLFS) initiated with Overweight rating and $23 (44% upside) price target at Stephens.
BioTelemetry (NASDAQ:BEAT) initiated with Buy rating and $58 (21% upside) price target at SunTrust.
Bruker (NASDAQ:BRKR) initiated with Overweight rating and $60 (18% upside) price target at Wells Fargo.
Charles River Labs (NYSE:CRL) initiated with Overweight rating and $180 (16% upside) price target at Wells Fargo.
Cryoport (NASDAQ:CYRX) initiated with Overweight rating and $21 (24% upside) price target at Stephens.
Danaher (NYSE:DHR) initiated with Overweight rating and $170 (9% upside) price target at Wells Fargo. Shares up 1% premarket.
Globus Medical (NYSE:GMED) initiated with Buy rating and $67 (16% upside) price target at SunTrust.
Halozyme Therapeutics (NASDAQ:HALO) initiated with Buy rating and $24 (33% upside) price target at Goldman Sachs.
Hologic (NASDAQ:HOLX) initiated with Equal Weight rating and $57 (9% upside) price target at Wells Fargo.
Horizon Therapeutics (NASDAQ:HZNP) resumed with Neutral rating and $35 (4% downside risk) price target at Goldman.
ICON Public Limited Company (NASDAQ:ICLR) initiated with Equal Weight rating and $180 (7% upside) price target at Wells Fargo.
Illumina (NASDAQ:ILMN) initiated with Underweight rating and $300 (9% downside risk) price target at Wells Fargo.
IRhythm Technologies (NASDAQ:IRTC) initiated with Buy rating and $102 (50% upside) price target at SunTrust.
Kodiak Sciences (NASDAQ:KOD) initiated with Buy rating and $115 (71% upside) price target at Roth Capital.
Labcorp (NYSE:LH) initiated with Overweight rating and $210 (24% upside) price target at Wells Fargo.
Medtronic (NYSE:MDT) initiated with Buy rating and $130 (14% upside) price target at SunTrust.
Mettler-Toledo (NYSE:MTD) initiated with Equal Weight rating and $815 (2% upside) price target at Wells Fargo.
Nevro (NYSE:NVRO) initiated with Buy rating and $132 (9% upside) price target at SunTrust.

Walgreens Boots EPS misses by $0.04, misses on revenue

Walgreens Boots (NASDAQ:WBA): Q1 Non-GAAP EPS of $1.37 misses by $0.04; GAAP EPS of $0.95 misses by $0.20.
Revenue of $34.34B (+1.6% Y/Y) misses by $110M.

Synthetic Bio up on advancement of co-lead candidate

Thinly traded nano cap Synthetic Biologics (SYN +8.7%) is up a 17x surge in volume in reaction to its update on co-lead candidate SYN-004 (ribaxamase).
Based on FDA feedback, a single-center three-arm Phase 1b/2a clinical trial, expected to start this quarter, will assess SYN-004 in up to 36 adults patients undergoing allogeneic hematopoietic cell transplantation (HCT) who have received intravenous beta-lactam antibiotics in response to fever. The primary objectives are safety, tolerability and pharmacokinetics.
The study will be conducted at the Washington University School of Medicine in St. Louis.
SYN-004 is an oral enzyme tablet that is co-administered with the antibiotics. By degrading beta-lactams, it helps maintain the normal balance of the gut microbiome and prevents unwanted effects such as diarrhea and Clostridium difficile infection.

FDA OKs new surgical approach for Abbott heart pump

Abbott (ABT -0.2%announces that the FDA has signed off on an alternative, less-invasive, surgical technique for its HeartMate 3 Left Ventricular Assist Device (LVAD) that will allow more advanced heart failure patients to avoid open heart surgery, the traditional way to implant an LVAD.
The procedure, called lateral thoracotomy, enables the placement of the device via an incision between the patient’s ribs to access the heart.
The FDA approved HeartMate 3 in August 2017 for short-term hemodynamic support in advanced heart failure patients. In October 2018, the agency approved it as a destination therapy (permanent use) in patients who are not eligible for transplant.

Genetic Tech up 95% on U.S. launch of breast cancer test

Thinly traded nano cap Genetic Technologies Limited (GENE +94.7%) rockets up on a whopping 333x surge in volume in reaction to the impending U.S. commercial launch of its GeneType for Breast Cancer test designed to assess breast cancer risk in patients at least 35 years old.
It plans to commence a limited release across 20 centers in eight states this quarter followed by full launch in Q2.

Collegium sees Xtampza sales as high as $160M this year

Collegium Pharmaceutical (NASDAQ:COLL) provides its 2020 outlook.
Xtampza ER (oxycodone) sales: $150M – 160M.
Nucynta (tapentadol) franchise sales: $170M – 180M.
Operating expenses: $130M – 140M.